The Rick Perry Merck Vioxx Kickback
By Approval Bush Abbott Part I
Texas Republican GOP Big Pharmaceutical Dope Pushers!
The Justice Department has this information and so do credible media sources and you ask me do I have proof?
I Think The Media Has Been Paid Off By Trump!
I intend to show proof that Dr. Gupta Played a Part in the Merck Vioxx Scandal and is doing the same with the Merck Vaccine. He is an actor not a doctor in my mind. After I show all the evidence, you will see connections, kickbacks, senseless deaths, and connections to birth defects related to the vaccine by executive order by Governor Rick Perry - After the Republican Primary.
Notes interpreted from Traditional Chinese [Best I could do an expert could do better] "Inside Trading Document Retrieved Legally Off The Web by Gregory N O'Dell." Was reported to the Justice Department for criminal prosecution by me after I made a plea to Greg Abbott attorney General of Texas for victim of crime compensation when I discovered the connection with George Bush and his kick man, Texas Governor Rick Perry.
The Clinton Administration had a safety concern presented to his office by the FDA that George Bush over-ruled by and executive order as the new President. Please note: "The first thing I will do when elected President is to Repeal the Obama Care Act (Rick Perry 09/18/2011)" Why? They do not care about people dying. The Teaparty is only interested in making money no matter who it kills and will take a kickback from anybody without any moral compass or remorse!
新浪网 - Jan 16, 2001
15年来，默克公司(Merck & Co.,MRK)药物研究所所长爱德华. ... 他从得克萨斯大学(University of Texas
15年来，默克公司(Merck & Co.,MRK)药物研究所所长爱德华. ... 他从得克萨斯大学(
Sina - Jan 16, 2001
15 Years, Merck (Merck & Co.,MRK) Medical Institute Director Edward . ... Him from theUniversity of Texas at (University of Texas
15 Years, Merck (Merck & Co.,MRK) Medical Institute Director Edward . ... Him from the
As the development of new drugs of Merck difficulties
http://finance.sina.com.cn 2001-01-16 11: 27 Dow Jones
For 15 years, Merck (Merck & Co., MRK), Edward Medical Institute-scolnic (Edward Scolnick) understands that the company will face this crisis now. He often secretly worried about independent Merck cannot survive this ordeal. "My suspicions never told anyone," said Dr scolnic.
Merck was that it several sales best drug patents expire. Some drugs (such as the treatment of hypertension Vasotec and Prinivil, treatment of high cholesterol, and to treat canker Mevacor Pepcid and Prilosec) General production, Merck lose a large part of the market share and profits. Almost every major pharmaceutical companies encounter such a problem.
Since investors were aware of this situation, Wall Street has been maintained that Merck should be added to the pharmaceutical industry to flourish in the merger. But the company's Chief Executive Officer of Raymond Gilmartin (.V. Raymond V. Gilmartin) on this firmly rejected, he firmly believed that Merck independently developing rapidly.
He is right. Today, Merck has passed. Analysts noted that revenue growth last year Merck has exceeded its fellow, and its revenue growth exceeded most of these companies. Although 2000 main market continued to drop, but Merck's stock is rising by 26%. The company has not faced the urgent need to save money, instead, it will examine expenditure increased nearly 17% of their sales team also expanded almost 1/3.
"Careful practice is to seek a merger, to strengthen the non-exclusive drug production, and maintain a diverse and comprehensive cost-cutting," Gilmartin said, "but this time we do not do these traditional experience. ”
Before entering the Merck, 59-year-old Jill Martin has led a medical device company. Gilmartin bet the pharmaceutical giant Merck's creative and innovative tradition makes the company out of trouble. On the contrary, the merge you could weaken the company's ability to innovate, and let this company as a distraction for several years.
If Jill Martin and his deputies made a mistake, Merck may have with Warner-lambotte company (WLA), Warner-Lambert, Upjohn, Syntex, Sandoz, Ciba-Geigy, Rhone-Poulenc and Hoechst and other companies, the outcome being died a natural death. These companies because of its laboratory cannot produce enough of the drug instead of patent expiration of old product, had to take a complicated way.
Merck's success proves that the pharmaceutical industry and Hollywood (Hollywood
This time, Merck, a Thai pharmacists Pepi-Pura Dixit (Peppi Prasit) to bring this inspiration. In July 1992, he roam a Montreal
After some time, Stephanie was 45-year-old Dr. Prakash Setra noticed a poster above said a Japanese company researchers claim they've produced a stimulating effect of painkillers, however this medicine in chemistry is not appropriate for the trial to on. Playa Setra immediately back to him in Montreal
Playa Dixit's work attracted the attention of scolnic. On the Playa Dixit's Painkiller project, scolnic said that he doesn't need a Committee to tell him this is a sensational projects, he knows that this is possible is the solution to the problem of Merck's patent.
This class is called non-steroidal anti-inflammatory drugs (e.g. aspirin (aspirin) and ibuprofen (ibuprofen)) of painkillers, over the years has not been a great improvement. Thousands of Americans every year because of drug side effects experienced by the ulcer, and thus can prevent such obviously would be a huge advance.
This class of drugs through control of prostaglandin build to eliminate causes pain with □. But prostaglandin are involved in manufacturing prevent digestive organs are affected by the erosion of the mucous membrane of the acid. A reliever of the anti-inflammatory effect, it will make the layer that protects the mucosa becomes thin, which increases the risk of bleeding ulcer.
However, in this field exploration, Playa Dixit and scolnic are worried that this will be a race, also expressed concern about the company behind. Because rumors have switched to Monsanto Co. (MON) of Larned Kalman, Ph.d., is developing a similar drugs.
So scolnic command Montreal
Playa Citadel Group synthesis hundreds of chemical compounds, some of which are compounds with extensive research, but in vitro experiments with rats but no clinical effect; there are also some compounds do not know what caused the death of a mouse. Until October 1994, the Group finally found two compounds, they passed the test, as well as mouse harmless, even hyper-dose use.
In General, scolnic is chosen to be expensive and risky human testing. However this project is so important, and Merck seemed to gamble with Monsanto so high competition, so he decided to place the two compounds are put into clinical trials.
This decision is completely correct, because both of these compounds in only one passed the test. "A failed and the other has a success, preclinical optical look of data is not possible to predict which compounds are to succeed," said scolnic.
At the same time, the remaining portion of the 1994 Gilmartin has other headache. The company later in the 1980s was beautiful, but in 1994, the company's growth rate has slowed down. Bill Clinton (Clinton
In that the first action in the development of common drug suppression measures and the sale of special agricultural chemicals and subsidiaries. He also commands the managed care companies at peace.
Merck has been resistance to those companies for reduced requirements, the result would be a company's products are increasingly excluded from large purchase group "prescription" manifest. American Healthcare Systems its Purchasing Partners LP is a large group purchasing organization. 1994 Gilmartin assumed office after the first week, and the Group's management personnel were conducted a meeting. Participation in this meeting of two participants said, Gilmartin commitment, Merck may in any condition in the group. At the end of 18 months, the managed care group on Merck product purchase quantity on the basis of the annual increase 10 times.
But most importantly, Gilmartin eventually decided to put the company's future lies in the company's experimental research work. Scolnic recalls: "to the company, he soon after to participate in our study meeting at a time, and stay with us. When he left, on the road, he said he wanted to talk with me. He also said: ‘ I want you to know that I am fully confident. You do your thing, I'm not going to interfere with you. ’”
This means you can freely take him all the resources needed to Playa citadel in Montreal
In January 1995, Merck with a set of potential new painkillers to Austin , Texas
Mr Tillich doctors perceived him as Merck test of a good chance of success. He said that this was the first time we saw good effect lasts so long-killers ".
At the same time, as Merck's conjecture, is developing a similar drug, Monsanto is also a similar test for screening of toothache. Their test was not successful. However, in the long term to reduce arthritis pain, Monsanto and Merck two companies of good, and a stimulating effect on the stomach is not.
The Merck was depressed, Monsanto was completed clinical studies. Merck behind one of the reasons is the dose pills, a small problem. The company found that each piece of the appropriate dose should be 12.5 to 25 mg per litre, while non-1,000 mg per litre. This dose pills particles is too small, Merck worry about arthritis inconvenience to hand pick so small tablets. So the company in tablets added some edible additives to increase the size of the tablets, but these additives and slow down the absorption of the drug. And so the researchers put these issues are resolved properly, have lost three months.
In 1998, the last day, the u.s.
In General, have a beginning, and to regain the advantage is very difficult. However Merck handles its new drug was put in the way it's named Vioxx Painkiller popularity does not lose to Celebrex. One reason is that Merck has expanded the role of marketing staff.
Gilmartin created by marketing, production and research in terms of staff, to plan long-term future. Supervision of Vioxx launch marketing Vice President Wendy-Dixon (Windy Dixon) said: "we decompose each task, what steps can be reduced. In this way, we can put products on the market of the normal process of shortening the 4 week or 5 weeks. ”
Although the team could manufacture a large number of bottles and boxes, but they can not be printed in advance, because the FDA tablets specification are not permitted to license before printing instructions. Due to a competitor's Painkiller has successfully, Merck challenge would be to FDA licensed copy of a few days, it is sent to the United States and Puerto Rico (Puerto Rico) parts of the printing press, immediately printed thousands of statement together with the tablets into packaging, and distributed to all pharmacies. Several aircraft were caught in the standby state, because printing plate must be rushed to all parts of the printing press.
Company insiders know, may 20, it is possible that the FDA issued a license. The company advanced specification designers Cherie-lamb plug-Wilton (Cheryl Ramsey-Weldon) mood waited a day, when she came home from work after continue, etc. "I sit on the phone," she said, "to my boss played three times to ask, at any time. ”
She finally received 10 o'clock in the evening. She wore Pajamas to jump into a car, rapidly to the factory. Four hours later, she took the design of good contributions to the two proof. 2.30 am, she went home to bed a couple of hours. To 6 points and rush back to continue the work.
Merck's printing work continuously for several days without downtime. Then, instruction is folded up and into the package. With good medicine bottle on Monday afternoon to all parts of the distribution center. Vioxx after being license 11 days to 4 000 pharmacies, this really is an impressive feat.
According to research firm IMS Health survey, Merck's Painkiller in launch 3 months after occupying the Cox-2 inhibitor "drug market nearly 1/3 ratio, 1 year occupancy close to 1/2. In Europe , Vioxx leading position, has in many countries the market beat Celebrex, although it registered late. According to several independent studies by two defeated Vioxx Celebrex: first, it is faster than Celebrex, the second is on the Cox-2 have more choice.
However, there are two kinds of drugs. Now joined Merck is another relevant competition of Cox-2, the competition is the Monsanto acquisition of Pharmacia Inc., the company (PHA), competition goals production such best-selling drugs improved second generation products.
These days, Gilmartin's mistaking the triumphant. He said: "many people are worried about Merck can compete, but we must be in each competition reached a new level. "However, Dr cornic memories of Vioxx, said:" if we originally selected two compounds in human trials did not succeed, and that we perhaps in a few years had to chance to rely on the fifth or sixth compounds to test, then we may become and now completely different company. ”(By GARDINER HARRIS)
他山之石：默克公司开发新药度难关
http://finance.sina.com.cn 2001年01月16日 11:27 道琼斯
15年来，默克公司(Merck & Co.,MRK)药物研究所所长爱德华.斯科尔尼克(Edward Scolnick)深知公司将面临现在这种危机。他经常暗自担心独立的默克公司不能度过这个难关。“我的这些怀疑从未告诉过任何人，”斯科尔尼克博士说。
默克的问题是：它几种销路最好的药品的专利权即将到期。一些药物(如治疗高血压的Vasotec和Prinivil、治疗高胆固醇的Mevacor以及治疗溃疡病的Pepcid和Prilosec等)的普遍生产，将令默克丧失很大一部分市场占有率和利润。差不多每一家大制药公司都会遇到这样的问题。
自从投资者们注意到这一情况後，华尔街就一直坚持认为，默克应加入到制药业盛行的兼并浪潮中去。但该公司首席执行长雷蒙德.V.吉尔马丁(Raymond V. Gilmartin)对此坚定地予以拒绝，他坚信默克能够独立迅速发展。
他是对的。如今，默克已经度过难关，神气十足。分析家们指出，默克去年的收入增长率超过了它的同行们，而且其收益的增长也超过了其中的大多数公司。虽然2000年主要市场不断下滑，但默克的股票却上扬了26%。该公司并未面临节约资金的迫切需要，取而代之的是，它将研究开支提高了近17%，还把销售队伍也扩大了几乎1/3。
“稳妥的做法是，寻求合并、加强非专属药物的生产、保持多样化和全面削减成本，”吉尔马丁说，“但这次我们没有按这些传统的经验做。”
在进入默克以前，现年59岁的吉尔马丁曾领导过一个医疗设备公司。吉尔马丁打赌默克这个制药业巨头的创造和革新传统能使公司摆脱困境。相反，合并则可能削弱公司的创新能力，并让公司为此分心好几年。
如果吉尔马丁和他的副手们犯了错误，默克也可能已经跟沃纳-兰博特公司(Warner-Lambert,WLA)、Upjohn、Syntex、Sandoz、Ciba-Geigy、Rhone-Poulenc和Hoechst等公司一样，落得个寿终正寝的结局。上述这些公司都是因为其实验室无法生产出足够的新药来代替专利到期的老产品，而不得不采取了合并的办法。
默克的成功证明，制药行业也与好莱坞(Hollywood
这次，默克的一位泰裔药剂师佩皮.普拉西特(Peppi Prasit)为公司带来了这种灵感。1992年7月，他漫步於蒙特利尔一个并不著名的医学会议上。在与一位同事闲聊时，他得知：默克的一些研究人员已经开始了一项实验室试验，以确定一种止痛药不太会像大多数治疗疼痛和关节炎的药物那样引起肠胃不适。
过了一段时间，现年45岁的普拉西特博士注意到一份宣传海报，上面说一家日本公司的研究人员宣称他们已生产出一种无刺激作用的止痛药，然而这种药在化学上不适宜试用於人。普拉西特立即回到他在蒙特利尔的实验室，编制出这一神秘的分子，并将其引入默克的新试验。当试验通过以後，他开始尝试创造出一种适用於人的类似药品。
普拉西特的工作引起了斯科尔尼克的关注。对普拉西特博士的止痛药项目，斯科尔尼克说，他不需要一个委员会来告诉他这是一个有潜力一鸣惊人的项目，他知道这有可能是解决默克专利问题的重要手段。
这类被称为非类固醇抗炎药物(如阿斯匹林(aspirin)与布洛芬(ibuprofen))的止痛药，多年来未曾有大的改进。数千美国人每年都因药物副作用而遭受溃疡之苦，因此能够防止这种副作用显然将是一个巨大进步。
这类药物通过控制前列腺素的生成来消除导致疼痛的炎□。但是前列腺素也参与制造防止内脏受消化酸侵蚀的粘膜。一种止痛药的抗炎效果越好，它就越会使这层保护粘膜变薄，从而增大了出血溃疡的风险。
华盛顿大学(Washington University
但是在这场探索中，普拉西特和斯科尔尼克担心这会是一场竞赛，也担心公司可能落後。因为传闻已跳槽到Monsanto Co. (MON)的尼德尔曼博士正在研制一种类似的药物。
所以斯科尔尼克命令蒙特利尔的研究人员要尽可能快地从事普拉西特的研究。
普拉西特小组合成了几百种化合物，其中有些化合物通过大量的试管研究，但对於实验用老鼠却无临床效果；还有一些化合物不知什麽原因使老鼠死亡。直到1994年10月，这个小组终於找到两种化合物，它们既通过了试管试验，同时也对老鼠无害，即使超剂量使用也无妨。
在一般情况下，斯科尔尼克会在其中选一种来进行昂贵和风险较大的人体试验。但是这一项目是如此重要，而且默克似乎在与Monsanto作赌注如此之高的竞争，於是他决定同时把这两种化合物都投入临床试验。
这一决定完全正确，因为这两种化合物中只有一种通过了试验。“一个失败而另一个却获得成功，光看临床前的数据是不可能预测出哪一种化合物会获得成功的，”斯科尔尼克说。
与此同时，1994年到任的吉尔马丁有其他的头痛之事。该公司在80年代後期一度风光无限，但在1994年，公司的增长率已经慢下来了。克林顿(Clinton
在他所采取的第一批行动中，就有抑制发展普通药物的措施以及出售专门化学品和农业子公司。他还命令经理们与管理式照护公司和平相处。
默克公司曾一直抵抗那些公司有关打折扣的要求，其结果就是公司的产品越来越多地被排除在大购买集团的“处方”清单之外。American Healthcare Systems属下的Purchasing Partners LP是一家大型集团采购组织。1994年吉尔马丁上任後的第一个星期，就与这个集团的管理人员们进行了一次会谈。参与这次会谈的两位参加者说，吉尔马丁承诺，默克公司愿在任何条件下与该集团合作。在後来的18个月中，这个管理式照护集团将对默克公司产品的采购量在年度基础上提高了10倍。
但最为重要的是，吉尔马丁後来决定把公司的未来寄托在公司的实验研究工作上。斯科尔尼克回忆道：“到公司後不久，他就来参加了我们的一次研究会议，并留下来与我们一起晚餐。当他离开时，在路上他说他想与我谈一谈。他还说：‘我想让你知道，我对你完全有信心。你尽管做你的事，我不会来干扰你。’”
这就意味著他可以自由地把他所需要的所有资源都投到普拉西特在蒙特利尔的项目上。
1995年1月，默克公司把一批潜在的新止痛药交给了得克萨斯州奥斯汀(Austin University of Texas
麦利希医生感觉到他为默克公司试验的止痛药成功的可能性很大。他说，这是“第一次我们见到良好效果能持续这麽长时间的止痛药”。
与此同时，正如默克公司的猜想，正在研制类似药物的Monsanto也在通过类似的牙痛试验进行筛选。他们的试验没有成功。但是，在减轻关节炎的长期疼痛方面，Monsanto与默克两家公司的止痛药效果都很好，而且对肠胃没有刺激作用。
使默克公司感到沮丧的是，Monsanto率先完成了临床研究。默克落後的原因之一是药片的剂量出了一点小问题。公司发现每片适当的剂量应该是12.5到25毫克，而非1,000毫克。这样剂量的药片颗粒太小，默克担心关节炎患者不便於用手拿取这麽小的药片。於是公司在药片中加了一些可食用的添加剂以增加药片的大小，但这些添加剂又减慢了药物的吸收。等研究者们把这些问题都解决妥当後，已经损失了三个月的时间。
在1998年最後一天，美国食品和药物管理局(Food and Drug Administration,简称FDA)许可Monsanto销售其名为Celebrex的无刺激止痛药。1999年2月，Monsanto开始与辉瑞制药有限公司(Pfizer Inc.,PFE，简称辉瑞公司)共同行销这种药品，并很快成了美国历史上最成功的新药投放事例。而默克公司此时仍未获得行销许可。
一般情况下，拥有这样一个开始，并要想重新夺回优势是很困难的。然而默克公司处理其新药投放的方式却令它名为Vioxx的止痛药热门程度不输於Celebrex。其中一个原因就是默克公司扩大了行销人员的作用。
吉尔马丁创建了由行销、生产和科研三方面人员组成的队伍，以计划远期未来的事情。监管Vioxx投放市场的行销副总裁温迪.狄克逊(Windy Dixon)说：“我们分解每一个任务，看有哪些步骤可以精减。这样，我们就可把产品投放市场的正常过程缩短4周或5周。”
虽然这个队伍能预先制造大量瓶子和包装盒，但他们不可能预先印刷药片说明书，因为FDA不允许在许可日之前印刷说明书。由於竞争对手的止痛药已经成功，默克公司面临的挑战就是在拿到FDA许可副本後的数天内，就将它送到美国和波多黎各(Puerto Rico )各地的印刷厂，立即印出几千份说明书，随药片一起装入包装中，并分发到各地的药房。数架飞机都处於待命状态，因为印刷板必须被火速送往各地的印刷厂。
公司内部人员都知道，5月20日有可能是FDA发出许可的日子。公司高级说明书设计师切丽.兰姆塞-威尔顿(Cheryl Ramsey-Weldon)焦虑不安地等了足足一天，当她下班回到家後还继续等。“我坐在电话机旁，”她说，“给我的上司打了三次电话询问情况，随时保持密切联系。”
她终於在晚上10点钟接到电话。她穿著睡衣就跳进汽车，飞速赶到工厂。4个小时後，她把设计好的稿件交给了两个校对员校对。凌晨2:30，她回家睡了几个小时。到6点又赶回来继续工作。
默克公司的印刷厂连续工作了几天没有停工。然後，说明书被折叠好并塞进包装中。装好药的瓶子在星期一下午运到各地的分销中心。Vioxx在被许可後的11天内就进入到4万家药房中了，这真是一次不同寻常的壮举。
根据研究公司IMS Health的调查，默克公司的止痛药在投放市场3个月後，就占据了“Cox-2抑制剂”类新药市场近1/3的比例，1年之内占有率就接近1/2。在欧洲，Vioxx占主导地位，已经在许多国家的市场上打败了Celebrex，尽管它注册较晚。根据几份独立的研究，Vioxx靠两点击败了Celebrex：一是它的作用比Celebrex快，二是对Cox-2有更大的选择性。
然而，两种药都有缺点。现在默克公司正加入了又一个有关Cox-2的竞争，竞争对手是收购了Monsanto的法玛西亚公司(Pharmacia Inc.,PHA)，竞争目标在於生产这类畅销药品经过改良的第二代产品。
这些天来，吉尔马丁有点情不自禁地洋洋得意起来。他说：“许多人都担心默克公司是否还能在竞争中取胜，但我们一定会在每次竞争中达到一个新水平。”但是斯科尔尼克博士在回忆Vioxx的开发时说：“如果我们最初选择的两种化合物在人体试验中没有成功，那我们也许在数年後还得碰运气依靠第五种或第六种化合物来进行试验，那麽我们也许会变成与现在完全不一样的公司了。”(By GARDINER HARRIS)
No comments:
Post a Comment
Many people have complained that they can not add comments to my blog. It is not me. I do not censor. I reported the problem to google. If you can not post to this blog and want to, then just email me at arctotraveler@gmail.com . I will make sure your message is posted just like Whataburger "The Way You Want It!"